CYP2C19 and acute coronary syndrome: For example, CYP2C19 intermediate and poor metabolizers (21.7%) would require the prescription of an alternate antiplatelet therapy such as prasugrel or ticagrelor instead of clopidogrel, especially when treating patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)23.